Harrow (HROW) delivered the revenue acceleration it had promised, but the more consequential news was what it cost. Third-quarter revenue reached a record $99.3 million, up 38.6% year over year and 0.9% above the $98.44 million consensus. Earnings of $0.12 per share missed the $0.13 consensus by 7.7% and fell 63.6% from a year ago. Reported GAAP diluted EPS was $0.25, but that figure includes a $5.0 million one-time litigation settlement gain, so it overstates the underlying earnings power. The central tension is clear. The top line is inflecting, yet management cut its full-year Adjusted EBITDA guidance roughly in half, from $80-$100 million to "more than $40 million." That range had been reiterated on every prior call this year.

The sequential revenue progression is genuinely strong: $44.2 million in Q1, $70.7 million in Q2 and $99.3 million in Q3. Branded products contributed $83.5 million, up 62%, and now make up about 84% of sales. VEVYE was the standout at a record $39.7 million, up from $29.4 million in Q2 and $20.9 million in Q1. Revenue grew 35% sequentially while prescriptions grew 17%, a sign that payer-mix economics are improving rather than volume alone driving the gain. TRIESENCE posted record unit demand of 20,022, more than double the year-ago level.

The profit picture is less convincing. Adjusted EBITDA swung to $21.2 million from a $1.2 million loss in Q2, but it was still below the $22.8 million earned a year ago on far less revenue. Operating income slipped to $11.5 million from $14.7 million because spending outran growth:

• SG&A rose to $53.1 million from $35.9 million.
• R&D roughly tripled to $10.3 million.

Gross margin recovered to 75% from 71% in Q2. However, it was flat year over year and short of the high-70s level management had pointed to last quarter, with compounding margins and mix cited as drags. Nine-month Adjusted EBITDA stands at just $7.3 million versus $37.8 million a year ago.

The new guidance asks investors to believe in a very large fourth quarter. Management reaffirmed $350-$365 million in revenue, which implies roughly $136-$150 million in Q4, a 37%-51% sequential step-up. It also guided to more than $33 million of Q4 Adjusted EBITDA. CEO Mark Baum acknowledged the revenue target "will require strong execution" and called the EBITDA outlook a floor. He attributed the cut to the first-half shortfall plus deliberate spending:

• accelerating the G-MELT NDA, now expected before year-end versus 1H27 previously;
• advancing development programs;
• integrating TYRVAYA, which closed October 1, added about 40 reps and is guided to contribute more than $30 million in 2027.

Additional tailwinds include a third VEVYE coverage win of 2026, covering 10+ million lives effective January, the launch of the HarrowRx prescribing platform, and IHEEZO's seasonally strongest quarter.

Bears have legitimate ammunition beyond the guidance cut:

• **QUELL trial miss:** The Phase 4 study of IHEEZO failed its primary non-inferiority endpoint (55.2% vs. 59.7%), and management is leaning on secondary tolerability data.
• **IHEEZO demand:** Unit demand dipped about 5% sequentially to 62,210.
• **BYOOVIZ launch:** Ordering ran behind the internal model, with accounts described as wide but shallow.
• **License risk:** A 10-Q disclosure flags that the TYRVAYA deal may breach the VEVYE license with Novaliq. Discussions with the licensor are ongoing.
• **Balance sheet:** Cash fell to $75.3 million from $83.9 million at Q2 after the $30 million TYRVAYA upfront payment. Notes payable sit near $293 million against stockholders' equity of only $28.8 million. Nine-month operating cash flow was an outflow of $27.4 million versus an inflow of $35.5 million a year earlier.

This leveraged profile leaves little room for a Q4 stumble.

The market had already turned skeptical before the report. Shares were at $27.47, down 29.6% from the $39.00 open after the August report and about 27% below the 200-day moving average of $37.81. Investor sentiment remained negative and weakened modestly, from -0.31 to -0.37, consistent with an audience that had grown wary of repeated EBITDA reaffirmations. The Earnings Whispers trend signals are split: price and AVWAP trends are negative while sequential growth is positive. That split mirrors the fundamental divide between improving revenue momentum and a deteriorating profit trajectory.

The bottom line is that Harrow showed real commercial traction, led by VEVYE pricing and volume, TRIESENCE demand and a pipeline that is moving faster. However, the halved EBITDA outlook, the QUELL miss, the Novaliq license question and a stretched balance sheet undercut the credibility of the profit story. The reaffirmed revenue guide rests on a record-shattering fourth quarter, so Q4 execution is now the decisive test of whether this quarter marks an inflection or another reset.